Takeda’s oral TYK2 blocker outperforms Sotyktu in PsO trial

Clinical Trials Arena·Jun 12

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Takeda's oral tyk2 blocker has performed well in a phase 3 trial for psoriasis, with some reports indicating it outperformed Bristol Myers' Sotyktu. The trial results suggest the drug, known as zasocitinib, may offer a promising oral treatment option for psoriasis. A filing for US regulatory approval is anticipated, potentially as early as 2026.

Full coverage

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

Yahoo Finance·Jun 11

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

Yahoo Finance·Jun 11

Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

Fierce Biotech·Jun 11

Takeda’s zasocitinib meets phase III psoriasis endpoints

BioWorld News·Jan 8

Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success

Fierce Biotech·Dec 18

Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

Yahoo Finance·Mar 31

Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight

Yahoo Finance·Jan 7

Pharmazz Presents Positive Phase IV Interim Analysis of Sovateltide for Acute Ischemic Stroke at the International Stroke Conference 2026

Yahoo Finance·Feb 4

View original report at Clinical Trials Arena ↗

Fetching the latest headlines…